ArticleGynecologic oncology2016

Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.

Brooke A Schlappe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.